

Jasper J Brugts

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5039881/publications.pdf>

Version: 2024-02-01

78
papers

1,438
citations

430442

18
h-index

395343

33
g-index

78
all docs

78
docs citations

78
times ranked

2072
citing authors

#	ARTICLE	IF	CITATIONS
1	CT-derived fractional flow reserve (FFR _{ct}) for functional coronary artery evaluation in the follow-up of patients after heart transplantation. <i>European Radiology</i> , 2022, 32, 1843-1852.	2.3	5
2	CardioMEMS [®] : a tool for remote hemodynamic monitoring of chronic heart failure patients. <i>Future Cardiology</i> , 2022, 18, 173-183.	0.5	7
3	Diabetes and treatment of chronic heart failure in a large real-world heart failure population. <i>ESC Heart Failure</i> , 2022, 9, 353-362.	1.4	13
4	Cardiac allograft vasculopathy and donor age affecting permanent pacemaker implantation after heart transplantation. <i>ESC Heart Failure</i> , 2022, 9, 1239-1247.	1.4	6
5	Heart failure with preserved, mid-range, and reduced ejection fraction across health care settings: an observational study. <i>ESC Heart Failure</i> , 2022, 9, 363-372.	1.4	17
6	Improved survival of left ventricular assist device carriers in Europe according to implantation eras: results from the PCHF [®] VAD registry. <i>European Journal of Heart Failure</i> , 2022, 24, 1305-1315.	2.9	10
7	Evaluation of patients with a HeartMate 3 left ventricular assist device using echocardiographic particle image velocimetry. <i>Journal of Ultrasound</i> , 2021, 24, 499-503.	0.7	3
8	Impact of sex differences in comorbidities and medication adherence on outcome in 25,776 heart failure patients. <i>ESC Heart Failure</i> , 2021, 8, 63-73.	1.4	15
9	Remote Monitoring in Chronic Heart Failure Patients: Is Non-Invasive Remote Monitoring the Way to Go?. <i>Sensors</i> , 2021, 21, 887.	2.1	19
10	Reply to Aortic valve surgery and left ventricular assist device: lights and shadows [™] . <i>European Journal of Heart Failure</i> , 2021, 23, 842-843.	2.9	0
11	Clinical Update of the Latest Evidence for CardioMEMS Pulmonary Artery Pressure Monitoring in Patients with Chronic Heart Failure: A Promising System for Remote Heart Failure Care. <i>Sensors</i> , 2021, 21, 2335.	2.1	13
12	Invasive Devices and Sensors for Remote Care of Heart Failure Patients. <i>Sensors</i> , 2021, 21, 2014.	2.1	19
13	Influence of renal insufficiency pre-heart transplantation on malignancy risk post-heart transplantation. <i>ESC Heart Failure</i> , 2021, 8, 2172-2182.	1.4	2
14	The effect of transcatheter aortic valve implantation on pulmonary artery pressures in a patient suffering from chronic heart failure: a case report. <i>European Heart Journal - Case Reports</i> , 2021, 5, ytab112.	0.3	2
15	Remote Monitoring of Heart Failure in Patients with Implantable Cardioverter-Defibrillators: Current Status and Future Needs. <i>Sensors</i> , 2021, 21, 3763.	2.1	10
16	Left ventricular remodelling and prognosis after discharge in new-onset acute heart failure with reduced ejection fraction. <i>ESC Heart Failure</i> , 2021, 8, 2679-2689.	1.4	5
17	COVID-19-related myocarditis post-heart transplantation. <i>International Journal of Infectious Diseases</i> , 2021, 107, 34-36.	1.5	3
18	Safety and feasibility of hemodynamic pulmonary artery pressure monitoring using the CardioMEMS device in LVAD management. <i>Journal of Cardiac Surgery</i> , 2021, 36, 3271-3280.	0.3	13

#	ARTICLE	IF	CITATIONS
19	Heart failure and promotion of physical activity before and after cardiac rehabilitation (HFâ€œProACH): a study protocol. ESC Heart Failure, 2021, 8, 3621-3627.	1.4	2
20	Remote hemodynamic guidance before and after left ventricular assist device implantation: short-term results from the HEMO-VAD pilot study. Future Cardiology, 2021, 17, 885-898.	0.5	8
21	Clinical implementation of coronary computed tomography angiography for routine detection of cardiac allograft vasculopathy in heart transplant patients. Transplant International, 2021, 34, 1886-1894.	0.8	9
22	Cardiovascular implantable electronic device therapy in patients with left ventricular assist devices: insights from TRAViATA. International Journal of Cardiology, 2021, 340, 26-33.	0.8	4
23	2D-echocardiography vs cardiac MRI strain: a prospective cohort study in patients with HER2-positive breast cancer undergoing trastuzumab. Cardiovascular Ultrasound, 2021, 19, 35.	0.5	7
24	Reply to Imamura. European Journal of Cardio-thoracic Surgery, 2020, 57, 410.	0.6	0
25	Mycobacterium chelonae, an â€œatypicalâ€™ cause of an LVAD driveline infection. International Journal of Infectious Diseases, 2020, 92, 127-129.	1.5	9
26	Impact of preoperative liver dysfunction on outcomes in patients with left ventricular assist devices. European Journal of Cardio-thoracic Surgery, 2020, 57, 920-928.	0.6	9
27	The Association Between Cytomegalovirus Infection and Cardiac Allograft Vasculopathy in the Era of Antiviral Valganciclovir Prophylaxis. Transplantation, 2020, 104, 1508-1518.	0.5	16
28	Mechanical Support in Early Cardiogenic Shock: What Is the Role of Intra-aortic Balloon Counterpulsation?. Current Heart Failure Reports, 2020, 17, 247-260.	1.3	19
29	Aortic root thrombus after left ventricular assist device implantation and aortic valve replacement. ESC Heart Failure, 2020, 7, 3208-3212.	1.4	3
30	Serially Measured Cytokines and Cytokine Receptors in Relation to Clinical Outcome in Patients With Stable Heart Failure. Canadian Journal of Cardiology, 2020, 36, 1587-1591.	0.8	2
31	Treatment Differences in Chronic Heart Failure Patients With Reduced Ejection Fraction According to Blood Pressure. Circulation: Heart Failure, 2020, 13, e006667.	1.6	16
32	Cardiac monitoring in HER2-positive patients on trastuzumab treatment: A review and implications for clinical practice. Breast, 2020, 52, 33-44.	0.9	26
33	Contemporary use of devices in chronic heart failure in the Netherlands. ESC Heart Failure, 2020, 7, 1771-1780.	1.4	6
34	A registryâ€œbased algorithm to predict ejection fraction in patients with heart failure. ESC Heart Failure, 2020, 7, 2388-2397.	1.4	13
35	Atrial fibrillation in chronic heart failure patients with reduced ejection fraction: The CHECK-HF registry. International Journal of Cardiology, 2020, 308, 60-66.	0.8	9
36	Temporal patterns of macrophageâ€œand neutrophilâ€œrelated markers are associated with clinical outcome in heart failure patients. ESC Heart Failure, 2020, 7, 1190-1200.	1.4	17

#	ARTICLE	IF	CITATIONS
37	Pulmonary artery pressureâ€­guided therapy in ambulatory patients with symptomatic heart failure: the CardioMEMS European Monitoring Study for Heart Failure (MEMSâ€­CHF). <i>European Journal of Heart Failure</i> , 2020, 22, 1891-1901.	2.9	142
38	Medical treatment of octogenarians with chronic heart failure: data from CHECK-HF. <i>Clinical Research in Cardiology</i> , 2020, 109, 1155-1164.	1.5	12
39	Monitoring pulmonary pressures during longâ€­term continuousâ€­flow left ventricular assist device and fixed pulmonary hypertension: redefining alleged pathophysiological mechanisms?. <i>ESC Heart Failure</i> , 2020, 7, 702-704.	1.4	3
40	Incidence of endâ€­stage renal disease after heart transplantation and effect of its treatment on survival. <i>ESC Heart Failure</i> , 2020, 7, 533-541.	1.4	29
41	Biatrial Versus Bicaval Orthotopic Heart Transplantation: A Systematic Review and Meta-Analysis. <i>Annals of Thoracic Surgery</i> , 2020, 110, 684-691.	0.7	15
42	Renal tubular damage and worsening renal function in chronic heart failure: Clinical determinants and relation to prognosis (Bioâ€­SHIFT study). <i>Clinical Cardiology</i> , 2020, 43, 630-638.	0.7	9
43	Remote monitoring for better management of LVAD patients: the potential benefits of CardioMEMS. <i>General Thoracic and Cardiovascular Surgery</i> , 2020, 68, 209-218.	0.4	15
44	Emerging electromagnetic interferences between implantable cardioverter-defibrillators and left ventricular assist devices. <i>Europace</i> , 2020, 22, 584-587.	0.7	22
45	Discontinuation of Angiotensin Converting Enzyme Inhibitors due to Dry Cough: Incidence and Clinical Determinants. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 105, 563-563.	2.3	2
46	Cardiac implantable electronic devices with a defibrillator component and allâ€­cause mortality in left ventricular assist device carriers: results from the PCHFâ€­VAD registry. <i>European Journal of Heart Failure</i> , 2019, 21, 1129-1141.	2.9	27
47	NT-proBNP correlates with LVEF decline in HER2-positive breast cancer patients treated with trastuzumab. <i>Cardio-Oncology</i> , 2019, 5, 4.	0.8	11
48	Subsequent Event Risk in Individuals With Established Coronary Heart Disease. <i>Circulation Genomic and Precision Medicine</i> , 2019, 12, e002470.	1.6	17
49	Pulmonary artery pressure telemonitoring by CardioMEMS in a patient pre- and post-left ventricular assist device implantation. <i>European Journal of Cardio-thoracic Surgery</i> , 2019, 56, 809-810.	0.6	8
50	Age differences in contemporary treatment of patients with chronic heart failure and reduced ejection fraction. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 1399-1407.	0.8	31
51	Contemporary Drug Treatment ofâ€­Chronic Heart Failure With Reducedâ€­Ejection Fraction. <i>JACC: Heart Failure</i> , 2019, 7, 13-21.	1.9	122
52	Design and rationale of haemodynamic guidance with CardioMEMS in patients with a left ventricular assist device: the HEMOâ€­VAD pilot study. <i>ESC Heart Failure</i> , 2019, 6, 194-201.	1.4	29
53	Monitoring pulmonary artery pressure in chronic heart failure patients and evaluating the treatment effect of MitraClip implantation for functional mitral regurgitation. <i>EuroIntervention</i> , 2019, 15, 418-419.	1.4	5
54	Incidence, predictors and clinical outcome of early bleeding events in patients undergoing a left ventricular assist device implant. <i>European Journal of Cardio-thoracic Surgery</i> , 2018, 54, 176-182.	0.6	20

#	ARTICLE	IF	CITATIONS
55	Preoperative right heart hemodynamics predict postoperative acute kidney injury after heart transplantation. <i>Intensive Care Medicine</i> , 2018, 44, 588-597.	3.9	52
56	Safety and feasibility of contrast echocardiography for the evaluation of patients with HeartMate 3 left ventricular assist devices. <i>European Heart Journal Cardiovascular Imaging</i> , 2018, 19, 690-693.	0.5	11
57	Challenges in Destination LVAD Therapy, Management of Mediastinitis and Device Infection, a Case Report. <i>Heart Lung and Circulation</i> , 2018, 27, e7-e10.	0.2	2
58	Pre-operative proteinuria in left ventricular assist devices and clinical outcome. <i>Journal of Heart and Lung Transplantation</i> , 2018, 37, 124-130.	0.3	17
59	Real-life Use of Neurohormonal Antagonists and Loop Diuretics in Chronic Heart Failure: Analysis of Serial Biomarker Measurements and Clinical Outcome. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 104, 346-355.	2.3	2
60	Cardiometabolic Biomarkers and Their Temporal Patterns Predict Poor Outcome in Chronic Heart Failure (Bio-SHIFT Study). <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 3954-3964.	1.8	27
61	Effectiveness of cardiovascular implantable electronic devices with a defibrillator component therapy according to ventricular assist device implant strategy: data from the PCHF-VAD registry. <i>Cardiologia Croatica</i> , 2018, 13, 358-360.	0.0	0
62	Short-term mechanical circulatory support as a bridge to durable left ventricular assist device implantation in refractory cardiogenic shock: a systematic review and meta-analysis. <i>European Journal of Cardio-thoracic Surgery</i> , 2017, 52, 14-25.	0.6	106
63	Individualized Angiotensin-Converting Enzyme (ACE) Inhibitor Therapy in Stable Coronary Artery Disease Based on Clinical and Pharmacogenetic Determinants: The PERindopril GENetic (PERGENE) Risk Model. <i>Journal of the American Heart Association</i> , 2016, 5, e002688.	1.6	16
64	Impact of renin-angiotensin system inhibitors on mortality and major cardiovascular endpoints in hypertension: A number-needed-to-treat analysis. <i>International Journal of Cardiology</i> , 2015, 181, 425-429.	0.8	41
65	Prediction of absolute risk reduction of cardiovascular events with perindopril for individual patients with stable coronary artery disease – Results from EUROPA. <i>International Journal of Cardiology</i> , 2015, 182, 194-199.	0.8	11
66	Short-term mechanical circulatory support by veno-arterial extracorporeal membrane oxygenation in the management of cardiogenic shock and end-stage heart failure. <i>Expert Review of Cardiovascular Therapy</i> , 2014, 12, 145-153.	0.6	9
67	A cardiac diagnosis by contrast echocardiography. <i>Heart</i> , 2014, 100, 657-657.	1.2	6
68	Meta-Analysis Comparing Carvedilol Versus Metoprolol for the Prevention of Postoperative Atrial Fibrillation Following Coronary Artery Bypass Grafting. <i>American Journal of Cardiology</i> , 2014, 113, 565-569.	0.7	35
69	Optimizing treatment benefit: individualized therapy or the polypill?. <i>Nature Reviews Cardiology</i> , 2014, 11, 307-307.	6.1	1
70	Long-lasting symptoms and diagnostics in a patient with unrecognized right sided heart failure: Why listening to the heart is so important. <i>World Journal of Cardiology</i> , 2014, 6, 345.	0.5	2
71	Genetic influences of angiotensin-converting enzyme inhibitor response: an opportunity for personalizing therapy?. <i>Expert Review of Cardiovascular Therapy</i> , 2012, 10, 1001-1009.	0.6	4
72	A pharmacogenetic analysis of determinants of hypertension and blood pressure response to angiotensin-converting enzyme inhibitor therapy in patients with vascular disease and healthy individuals. <i>Journal of Hypertension</i> , 2011, 29, 509-519.	0.3	47

#	ARTICLE	IF	CITATIONS
73	Statin prescription in men and women at cardiovascular risk: to whom and when?. <i>Current Opinion in Cardiology</i> , 2010, 25, 484-489.	0.8	17
74	Tailored therapy of ACE inhibitors in stable coronary artery disease: pharmacogenetic profiling of treatment benefit. <i>Pharmacogenomics</i> , 2010, 11, 1115-1126.	0.6	17
75	The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trials. <i>European Heart Journal</i> , 2009, 30, 1385-1394.	1.0	54
76	Angiotensin-converting enzyme inhibition by perindopril in the treatment of cardiovascular disease. <i>Expert Review of Cardiovascular Therapy</i> , 2009, 7, 345-360.	0.6	22
77	Pharmacogenetics of ACE inhibition in stable coronary artery disease: steps towards tailored drug therapy. <i>Current Opinion in Cardiology</i> , 2008, 23, 296-301.	0.8	11
78	Renal Function and Risk of Myocardial Infarction in an Elderly Population. <i>Archives of Internal Medicine</i> , 2005, 165, 2659.	4.3	72